



PATENT

Client-Matter No.: 66654-668 (P-LJ 4857)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Ruoslahti and MacKenna

) Confirmation No: 3748

RECEIVED

) Group Art Unit: 1654

JAN 06 2004

Serial No.: 09/910,582

) Examiner: M. Audet

TECH CENTER 1600/2900

Filed: July 20, 2001

) CERTIFICATE OF MAILING BY "EXPRESS MAIL"
) "EXPRESS MAIL" MAILING LABEL NUMBER: EV 400 553 107 US
) DATE OF DEPOSIT: December 19, 2003

For: HEART HOMING
CONJUGATES

) I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE
) UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO
) ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE
) AND IS ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Paul Choi
Printed Name of Person Mailing Paper or Fee

Signature of Person Mailing Paper or Fee

RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the Restriction Requirement mailed September 19, 2003,
consideration of the following remarks is respectfully requested.

REMARKS

Claims 20-26, 30-33, 35 and 36 are pending in the application and have been
restricted under 35 U.S.C. § 121 into the following two groups:

Group I : Claims 20-26, 32, 33 and 35, drawn to a conjugate or
method of treating a cardiovascular disease using a peptide selected from SEQ ID NOS: 2, 3, 4,
9, or 10; and

Group II : Claims 31 and 36, drawn to a conjugate comprising a
peptide of any length or a length less than 100 amino acids.

The Examiner requests that one of the groups of claims be elected for
examination. Applicants note that claim 34 was not restricted as part of the present Office
Action. Applicants assume this was inadvertent on the Examiner's part and that claim 34 is
considered to be in Group I. Although the restriction requirement is traversed for the reasons set
forth below, Applicants elect the claims of Group I, claims 20-26 and 32-35, for examination.